Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes

被引：0
|
作者：
Goss, Christopher H. [1 ,2 ,3 ]
Vandevanter, Donald R. [4 ]
机构：
[1] Univ Washington, Dept Med, Seattle, WA 98195 USA
[2] Univ Washington, Dept Pediat, Seattle, WA 98195 USA
[3] Seattle Children s Res Inst, CF Therapeut Dev Network Coordinating Ctr, Seattle, WA 98101 USA
[4] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2024年 / 63卷 / 06期
基金：
美国国家卫生研究院;
关键词：
PULMONARY EXACERBATIONS; ANTIBIOTIC-TREATMENT; TRIAL; PLACEBO;
D O I：
10.1183/13993003.00858-2024
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Evidence continues to build regarding management of pulmonary exacerbation in cystic fibrosis. This editorial comments on the work by Waters and colleagues, noting evidence continues to build regarding the lack of efficacy of steroids in exacerbation. © 2024 European Respiratory Society. All rights reserved.
引用
收藏
页数：3
相关论文
共 50 条
  • [41] The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis
    Guevara, Maria Talamo
    McColley, Susanna A.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (11) : 1305 - 1311
  • [42] A safety evaluation of ivacaftor for the treatment of cystic fibrosis
    McColley, Susanna A.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (05) : 709 - 715
  • [43] Inhaled hypertonic saline in adults hospitalised for exacerbation of cystic fibrosis lung disease: a retrospective study
    Pezzulo, Alejandro A.
    Stoltz, David A.
    Hornick, Douglas B.
    Durairaj, Lakshmi
    BMJ OPEN, 2012, 2 (02):
  • [44] Blood Transcriptomic and Inflammatory Protein Biomarkers Associated with Imminent Pulmonary Exacerbation Risk in Cystic Fibrosis
    Dong, Kang
    Jang, Jiah
    Shannon, Casey P.
    Ng, Raymond
    Tebbutt, Scott J.
    Quon, Bradley S.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2024, 21 (12) : 1688 - 1697
  • [45] Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis
    Sequeiros, Iara Maria
    Jarad, Nabil
    CHRONIC RESPIRATORY DISEASE, 2012, 9 (01) : 9 - 16
  • [46] Intravenous antibiotic use and exacerbation events in an adult cystic fibrosis centre: A prospective observational study
    Hoo, Zhe Hui
    Bramley, Nicole R.
    Curley, Rachael
    Edenborough, Frank P.
    Walters, Stephen J.
    Campbell, Michael J.
    Wildman, Martin J.
    RESPIRATORY MEDICINE, 2019, 154 : 109 - 115
  • [47] A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis
    Paynter, Alex
    Khan, Umer
    Heltshe, Sonya L.
    Goss, Christopher H.
    Lechtzin, Noah
    Hamblett, Nicole Mayer
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (01) : 78 - 83
  • [48] Doxycycline improves clinical outcomes during cystic fibrosis exacerbations
    Xu, Xin
    Abdalla, Tarek
    Bratcher, Preston E.
    Jackson, Patricia L.
    Sabbatini, Gina
    Wells, J. Michael
    Lou, Xiang-Yang
    Quinn, Rebecca
    Blalock, J. Edwin
    Clancy, J. P.
    Gaggar, Amit
    EUROPEAN RESPIRATORY JOURNAL, 2017, 49 (04)
  • [49] Effects of new and emerging therapies on gastrointestinal outcomes in cystic fibrosis
    Houwen, Roderick H. J.
    van der Woerd, Wendy L.
    Slae, Mordechai
    Wilschanski, Michael
    CURRENT OPINION IN PULMONARY MEDICINE, 2017, 23 (06) : 551 - 555
  • [50] Unmet needs in cystic fibrosis: the next steps in improving outcomes
    West, Natalie E.
    Flume, Patrick A.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (07) : 585 - 593
12345